{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:30:00Z","timestamp":1771864200127,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hyog Medical University","award":["No munber"],"award-info":[{"award-number":["No munber"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Immune and inflammatory blood parameters have been reported as biomarkers for treatment efficacy. This study aimed to establish a predictive model that includes blood parameters for patients with metastatic breast cancer treated with eribulin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 297 patients were enrolled, and their baseline neutrophil-to-lymphocyte ratio, absolute lymphocyte count (ALC), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), lymphocyte-to-monocyte ratio (LMR), lactate dehydrogenase (LDH), C-reactive protein (CRP), and clinical data were retrospectively collected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We constructed nomograms to predict overall survival (OS) and progression-free survival (PFS) using blood parameters, including clinical factors. For OS, menopausal status, hormone receptor status, HER2 status, de novo or recurrent, metastatic site, treatment line, ALC, PLR, PNI, LMR, LDH, and CRP were selected to predict the model. We used menopausal status, hormone receptor status, HER2 status, treatment line, PLR, LMR, LDH, and CRP to predict PFS. Both the OS and PFS of patients according to the risk scores were significantly different (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The optimism-corrected C-indices of the nomograms for OS and PFS were 0.680 and 0.622, respectively. The mean time-dependent area under the receiver operating curve values for OS at 1, 2, and 3\u00a0years were 0.752, 0.761, and 0.784, respectively, and for PFS at 3, 6, and 12\u00a0months were 0.660, 0.661, and 0.650, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Nomograms incorporating peripheral blood parameters may improve the accuracy of predicting OS and PFS in patients treated with eribulin. Our prediction model may help decision-making for breast cancer patients who are considering eribulin treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12282-025-01678-7","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:31:21Z","timestamp":1740069081000},"page":"500-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters"],"prefix":"10.1007","volume":"32","author":[{"given":"Keiko","family":"Natori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Igeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nagahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadako","family":"Akashi-Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Daimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-4008","authenticated-orcid":false,"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"1678_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6.","journal-title":"Lancet"},{"key":"1678_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13058-018-1003-1","volume":"20","author":"MV Dieci","year":"2018","unstructured":"Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, et al. Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Res. 2018;20:62. https:\/\/doi.org\/10.1186\/s13058-018-1003-1.","journal-title":"Breast Cancer Res"},{"key":"1678_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clbc.2018.03.002","volume":"18","author":"Y Miyagawa","year":"2018","unstructured":"Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin Breast Cancer. 2018;18:400\u20139. https:\/\/doi.org\/10.1016\/j.clbc.2018.03.002.","journal-title":"Clin Breast Cancer"},{"key":"1678_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer. 2020;27:706\u201315. https:\/\/doi.org\/10.1007\/s12282-020-01067-2.","journal-title":"Breast Cancer"},{"key":"1678_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/mco.2024.2713","volume":"20","author":"H Shimada","year":"2024","unstructured":"Shimada H, Fujimoto A, Matsuura K, Kohyama S, Nukui A, Ichinose Y, et al. Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood-based parameters and ratio. Mol Clin Oncol. 2024;20:15. https:\/\/doi.org\/10.3892\/mco.2024.2713.","journal-title":"Mol Clin Oncol"},{"key":"1678_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21873\/cdp.10058","volume":"1","author":"Y Koyama","year":"2021","unstructured":"Koyama Y, Kawai S, Uenaka N, Okazaki M, Asaoka M, Teraoka S, et al. Absolute lymphocyte count, platelet-to-lymphocyte ratio, and overall survival in eribulin-treated HER2-negative metastatic breast cancer patients. Cancer Diagn Progn. 2021;1:435\u201341. https:\/\/doi.org\/10.21873\/cdp.10058.","journal-title":"Cancer Diagn Progn"},{"key":"1678_CR7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.21873\/anticanres.15553","volume":"42","author":"W Goto","year":"2022","unstructured":"Goto W, Kashiwagi S, Takada K, Asano Y, Morisaki T, Shibutani M, et al. Utility of follow-up with absolute lymphocyte count in patients undergoing eribulin treatment for early detection of progressive advanced or metastatic breast cancer. Anticancer Res. 2022;42:939\u201346. https:\/\/doi.org\/10.21873\/anticanres.15553.","journal-title":"Anticancer Res"},{"key":"1678_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12957-021-02441-w","volume":"19","author":"T Morisaki","year":"2021","unstructured":"Morisaki T, Kashiwagi S, Asano Y, Goto W, Takada K, Ishihara S, et al. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types. World J Surg Oncol. 2021;19:324. https:\/\/doi.org\/10.1186\/s12957-021-02441-w.","journal-title":"World J Surg Oncol"},{"key":"1678_CR9","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.21873\/anticanres.15095","volume":"41","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T. Dynamic changes in absolute lymphocyte counts during eribulin therapy are associated with survival benefit. Anticancer Res. 2021;41:3109\u201319. https:\/\/doi.org\/10.21873\/anticanres.15095.","journal-title":"Anticancer Res"},{"key":"1678_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12282-021-01232-1","volume":"28","author":"M Takahashi","year":"2021","unstructured":"Takahashi M, Inoue K, Mukai H, Yamanaka T, Egawa C, Miyoshi Y, et al. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan. Breast Cancer. 2021;28:945\u201355. https:\/\/doi.org\/10.1007\/s12282-021-01232-1.","journal-title":"Breast Cancer"},{"key":"1678_CR11","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.21873\/anticanres.14317","volume":"40","author":"S Kashiwagi","year":"2020","unstructured":"Kashiwagi S, Asano Y, Goto W, Takada K, Morisaki T, Kouhashi R, et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40:3345\u201354. https:\/\/doi.org\/10.21873\/anticanres.14317.","journal-title":"Anticancer Res"},{"key":"1678_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000507043","volume":"64","author":"A Ueno","year":"2019","unstructured":"Ueno A, Maeda R, Kin T, Ito M, Kawasaki K, Ohtani S. Utility of the Absolute lymphocyte count and neutrophil\/lymphocyte ratio for predicting survival in patients with metastatic breast cancer on eribulin: a real-world observational study. Chemotherapy. 2019;64:259\u201369. https:\/\/doi.org\/10.1159\/000507043.","journal-title":"Chemotherapy"},{"key":"1678_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe J, Saito M, Horimoto Y, Nakamoto S. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res Treat. 2020;181:211\u201320. https:\/\/doi.org\/10.1007\/s10549-020-05626-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1678_CR14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s12282-020-01069-0","volume":"27","author":"M Myojin","year":"2020","unstructured":"Myojin M, Horimoto Y, Ito M, Kitano S, Ishizuka Y, Sasaki R, et al. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast Cancer. 2020;27:732\u20138. https:\/\/doi.org\/10.1007\/s12282-020-01069-0.","journal-title":"Breast Cancer"},{"key":"1678_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.21873\/anticanres.14794","volume":"41","author":"T Oba","year":"2021","unstructured":"Oba T, Maeno K, Ono M, Ito T, Kanai T, Ito KI. Prognostic nutritional index is superior to neutrophil-to-lymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with eribulin. Anticancer Res. 2021;41:445\u201352. https:\/\/doi.org\/10.21873\/anticanres.14794.","journal-title":"Anticancer Res"},{"key":"1678_CR16","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.21873\/invivo.12903","volume":"36","author":"S Yamamoto","year":"2022","unstructured":"Yamamoto S, Adachi S, Wada T, Narui K, Kimura A, Oshi M, et al. The modified glasgow prognostic score and prognostic nutritional index as prognostic markers in patients with metastatic breast cancer treated with eribulin. In Vivo. 2022;36:1854\u20139. https:\/\/doi.org\/10.21873\/invivo.12903.","journal-title":"In Vivo"},{"key":"1678_CR17","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.21873\/anticanres.14414","volume":"40","author":"A Sata","year":"2020","unstructured":"Sata A, Fukui R, Miyagawa Y, Bun A, Ozawa H, Fujimoto Y, et al. C-reactive protein and absolute lymphocyte count can predict overall survival of patients treated with eribulin. Anticancer Res. 2020;40:4147\u201356. https:\/\/doi.org\/10.21873\/anticanres.14414.","journal-title":"Anticancer Res"},{"key":"1678_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1245\/s10434-012-2588-8","volume":"20","author":"B Deyarmin","year":"2013","unstructured":"Deyarmin B, Kane JL, Valente AL, van Laar R, Gallagher C, Shriver CD, et al. Effect of ASCO\/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol. 2013;20:87\u201393. https:\/\/doi.org\/10.1245\/s10434-012-2588-8.","journal-title":"Ann Surg Oncol"},{"key":"1678_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"1678_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical prediction models. A practical approach to development validation, and updating","author":"EW Steyerberg","year":"2019","unstructured":"Steyerberg EW. Clinical prediction models. A practical approach to development validation, and updating. New York: Springer; 2019."},{"key":"1678_CR21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00259-022-06082-3","volume":"50","author":"K Kitajima","year":"2023","unstructured":"Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. Eur J Nucl Med Mol Imaging. 2023;50:1487\u201398. https:\/\/doi.org\/10.1007\/s00259-022-06082-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1678_CR22","doi-asserted-by":"publisher","first-page":"882896","DOI":"10.3389\/fonc.2022.882896","volume":"12","author":"C Gianni","year":"2022","unstructured":"Gianni C, Palleschi M, Schepisi G, Casadei C, Bleve S, Merloni F, et al. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. Front Oncol. 2022;12:882896. https:\/\/doi.org\/10.3389\/fonc.2022.882896.","journal-title":"Front Oncol"},{"key":"1678_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41416-019-0556-9","volume":"121","author":"R Kaul","year":"2019","unstructured":"Kaul R, Risinger AL, Mooberry SL. Eribulin rapidly inhibits TGF-\u03b2-induced Snail expression and can induce Slug expression in a Smad4-dependent manner. Br J Cancer. 2019;121:611\u201321. https:\/\/doi.org\/10.1038\/s41416-019-0556-9.","journal-title":"Br J Cancer"},{"key":"1678_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P. Targeting TGF-\u03b2 Signaling in Cancer. Trends Cancer. 2017;3:56\u201371. https:\/\/doi.org\/10.1016\/j.trecan.2016.11.008.","journal-title":"Trends Cancer"},{"key":"1678_CR25","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.21037\/tcr-23-1078","volume":"12","author":"L Hao","year":"2023","unstructured":"Hao L, Dong J, Yu H, Chen J, Han X, Pan Y. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study. Transl Cancer Res. 2023;12:2726\u201341. https:\/\/doi.org\/10.21037\/tcr-23-1078.","journal-title":"Transl Cancer Res"},{"key":"1678_CR26","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.1038\/s41598-018-27075-z","volume":"8","author":"C Vernieri","year":"2018","unstructured":"Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. Sci Rep. 2018;8:8703. https:\/\/doi.org\/10.1038\/s41598-018-27075-z.","journal-title":"Sci Rep"},{"key":"1678_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/cancers11091243","volume":"11","author":"G Pelizzari","year":"2019","unstructured":"Pelizzari G, Basile D, Zago S, Lisanti C, Bartoletti M, Bortot L, et al. Lactate Dehydrogenase (LDH) response to first-line treatment predicts survival in metastatic breast cancer: first clues for a cost-effective and dynamic biomarker. Cancers (Basel). 2019;11:1243. https:\/\/doi.org\/10.3390\/cancers11091243.","journal-title":"Cancers (Basel)"},{"key":"1678_CR28","doi-asserted-by":"publisher","first-page":"10714","DOI":"10.18632\/oncotarget.24246","volume":"9","author":"Z Jia","year":"2018","unstructured":"Jia Z, Zhang J, Wang Z, Wang B, Wang L, Cao J, et al. An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. Oncotarget. 2018;9:10714\u201322. https:\/\/doi.org\/10.18632\/oncotarget.24246.","journal-title":"Oncotarget"},{"key":"1678_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.18632\/oncotarget.27423","volume":"11","author":"Y Miyagawa","year":"2020","unstructured":"Miyagawa Y, Yanai A, Yanagawa T, Inatome J, Egawa C, Nishimukai A, et al. Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget. 2020;11:86\u201398. https:\/\/doi.org\/10.18632\/oncotarget.27423.","journal-title":"Oncotarget"},{"key":"1678_CR30","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.23217","volume":"8","author":"A Diehl","year":"2017","unstructured":"Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 2017;8:114268\u201380. https:\/\/doi.org\/10.18632\/oncotarget.23217.","journal-title":"Oncotarget"},{"key":"1678_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12967-022-03359-x","volume":"20","author":"M Guida","year":"2022","unstructured":"Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, et al. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. J Transl Med. 2022;20:159. https:\/\/doi.org\/10.1186\/s12967-022-03359-x.","journal-title":"J Transl Med"},{"key":"1678_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3389\/fonc.2020.00913","volume":"10","author":"M Jiang","year":"2020","unstructured":"Jiang M, Peng W, Pu X, Chen B, Li J, Xu F, et al. Peripheral blood biomarkers associated with outcome in non-small cell lung cancer patients treated with nivolumab and durvalumab monotherapy. Front Oncol. 2020;10:913. https:\/\/doi.org\/10.3389\/fonc.2020.00913.","journal-title":"Front Oncol"},{"key":"1678_CR33","doi-asserted-by":"publisher","first-page":"103806","DOI":"10.1016\/j.critrevonc.2022.103806","volume":"179","author":"SE Rebuzzi","year":"2022","unstructured":"Rebuzzi SE, Prelaj A, Friedlaender A, Cortellini A, Addeo A, Genova C, et al. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol. 2022;179:103806. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103806.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1678_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3892\/etm.2023.12060","volume":"26","author":"Y Xu","year":"2023","unstructured":"Xu Y, Ma K, Zhang F, Ma M, Hong L, Wang J, et al. Association between baseline C-reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta-analysis. Exp Ther Med. 2023;26:361. https:\/\/doi.org\/10.3892\/etm.2023.12060.","journal-title":"Exp Ther Med"},{"key":"1678_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200936","volume":"13","author":"U Cho","year":"2018","unstructured":"Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS ONE. 2018;13: e0200936. https:\/\/doi.org\/10.1371\/journal.pone.0200936.","journal-title":"PLoS ONE"},{"key":"1678_CR36","doi-asserted-by":"publisher","first-page":"650980","DOI":"10.3389\/fonc.2021.650980","volume":"11","author":"Y Yin","year":"2021","unstructured":"Yin Y, Zhang Y, Li L, Zhang S, Liu N, Yuan S. Prognostic value of pretreatment lymphocyte-to-monocyte ratio and development of a nomogram in breast cancer patients. Front Oncol. 2021;11:650980. https:\/\/doi.org\/10.3389\/fonc.2021.650980.","journal-title":"Front Oncol"},{"key":"1678_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3892\/ol.2022.13552","volume":"24","author":"M Xiang","year":"2022","unstructured":"Xiang M, Zhang H, Tian J, Yuan Y, Xu Z, Chen J. Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer. Oncol Lett. 2022;24:432. https:\/\/doi.org\/10.3892\/ol.2022.13552.","journal-title":"Oncol Lett"},{"key":"1678_CR38","doi-asserted-by":"publisher","first-page":"14659","DOI":"10.1038\/s41598-022-18727-2","volume":"12","author":"MS Chen","year":"2022","unstructured":"Chen MS, Liu PC, Yi JZ, Xu L, He T, Wu H, et al. Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer. Sci Rep. 2022;12:14659. https:\/\/doi.org\/10.1038\/s41598-022-18727-2.","journal-title":"Sci Rep"},{"key":"1678_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.24976\/Discov.Med.202335176.29","volume":"35","author":"M Li","year":"2023","unstructured":"Li M, Liu M, Zhu L, Lu H, Mao A, Liu H, et al. Establishing a predictive model to predict survival of de novo metastatic HER2-low breast cancer: A National Cancer Database Analysis. Discov Med. 2023;35:283\u201392. https:\/\/doi.org\/10.24976\/Discov.Med.202335176.29.","journal-title":"Discov Med"},{"key":"1678_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cpt.2023.07.004","volume":"1","author":"L Ning","year":"2023","unstructured":"Ning L, Liu Y, Hou Y, Wang M, Shi M, Liu Z, et al. Survival nomogram for patients with de novo metastatic breast cancer based on the SEER database and an external validation cohort. Cancer Pathog Ther. 2023;1:253\u201361. https:\/\/doi.org\/10.1016\/j.cpt.2023.07.004.","journal-title":"Cancer Pathog Ther"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01678-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01678-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:02:33Z","timestamp":1749499353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01678-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01678-7","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YM received research funding and honoraria from Eisai, Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Kyowa-Kirin, Daiichi-Sankyo, and Taiho, and consulting fees from Daiichi-Sankyo. MI received consulting fees from Ono Pharmaceutical, Santen Pharmaceutical and Takeda Pharmaceutical. MN received honoraria from Chugai, AstraZeneca, Eli Lilly, Pfizer, Novartis, Taiho, Daiichi Sankyo, Eisai, Kyowa Kirin, and Denka. SA received payment for lectures from Eisai and the board members of JBCS, JABTS, JOPBS, and JBSGO. TD received consulting fees from Ajinomoto, Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo Company, Eisai, Ferring Pharmaceuticals, Healios, Ono Pharmaceutical, and Terumo Corporation. The other authors declare no conflicts of interest related this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Committee of the Hyogo College of Medicine (approval no. 1969). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study written informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}